Navigation Links
Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions in Serum Triglycerides in Preclinical Testing
Date:6/2/2011

nt to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Spherix Announces Registered Direct Offering of $2.77 Million
2. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
3. Spherix Announces Third Quarter 2010 Financial Results
4. Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
5. Spherix Announces Institutional Investors Purchase $5.25 Million of Convertible Preferred Stock and Warrants
6. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
7. Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
8. Spherix Reports Third Quarter 2009 Earnings
9. Spherix Announces Positive Phase 2 Study Results
10. Spherix Reports First Quarter 2009 Earnings
11. Spherix Elects New Independent Director, and Elects Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015  Diomics, an innovator in ... Weissman , global financial executive, has joined Diomics, board ... more than 25 years of industry experience in broad ... as a managing director at Credit Suisse and JP ... Stanley/Dean Witter. "Diomics is on the forefront ...
(Date:6/1/2015)... Research and Markets  ( http://www.researchandmarkets.com/research/4lw2mn/global_a_dialyzer ) ... A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor ) ... The Global A Dialyzer Reprocessing Machine ... a professional and in-depth study on the current ... The report provides a basic overview of ...
(Date:6/1/2015)... BROOK, N.J. , June 1, 2015 /PRNewswire/ ... Food and Drug Administration (FDA) has accepted for ... for Anthim® (obiltoxaximab) for the treatment and prevention ... was submitted on March 20, 2015. Anthim is ... National Stockpile, the U.S. government,s repository of critical ...
Breaking Medicine Technology:Richard M. Weissman joins Diomics Board of Directors 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 2Global A Dialyzer Reprocessing Machine (A Dialyzer Reprocessor) Industry Report 2014 - Development Trends Forecasts to 2020 3U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 3
... March 19 FluoroPharma Inc., a company,developing breakthrough ... (PET) market, announced commencement of Phase,I clinical trials ... the proposed studies. The Phase I trial is ... safety, distribution and dosimetry,of BFPET as a PET ...
... KNOLLS, N.J., March 19 Emisphere,Technologies, Inc. (Nasdaq: ... studies demonstrating that its proprietary eligen(R) technology,enhances the ... than were,used previously. The lower doses are believed ... the rate of absorption of B12 administered,with eligen(R) ...
Cached Medicine Technology:FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses 2Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses 3
(Date:6/1/2015)... June 02, 2015 The National ... Willey as a 2015-2016 inductee into its VIP ... with this prestigious distinction for leadership in safety, environment, ... networking organization exclusively for professional women, boasting more than ... "I’m pleased to present Lourinda with this important honor,” ...
(Date:6/1/2015)... 02, 2015 Dr. Robert ... Piedmont Physical Medicine & Rehabilitation, P.A., has published ... of stem cell therapy for knees, and highlights ... preferred alternative to arthroscopy or knee joint replacement. ... of Neuromusculoskeletal, Vascular and Regenerative Medicine, writes that ...
(Date:6/1/2015)... 01, 2015 Atagi Plastic Surgery and ... named an Ultherapy® Ultra Treatment Provider by ... Skin Aesthetics is one of only six practices in ... treatment provider. , Atagi Plastic Surgery and Skin ... area has led the practice to earn the distinction ...
(Date:6/1/2015)... 2015 The Muscular Dystrophy Association ... in participating in the sold out 2015 Bank ... secure guaranteed entry by signing up through the ... space is limited. , This national endurance program ... and abilities, and a supportive community of teammates, ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Note: Dr. ... development in breast cancer prevention. , A phase III ... that postmenopausal women with ductal carcinoma in situ (DCIS) ... and prevention. , The study (NSABP B-35/NRG Oncology) looked ... completed the standard five-year treatment with tamoxifen to those ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 3Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:Sold Out 2015 Bank of America Chicago Marathon and Marine Corps Marathon Entries Still Available through MDA Team Momentum 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 2Health News:Today at ASCO: Anastrazole Offers Higher Breast Cancer-Free Survival Rates than Tamoxifen Following DCIS, Phase III Study Shows 3
... complication that can occur in children affected by acute ... attack, pulmonary embolism and other cardiovascular diseases//. ... Italy by the Laboratory of Genetic and Environmental Epidemiology ... collaboration with the Haematology Division of the University of ...
... Prexige is said to be linked to an increased risk ... warned to exercise caution in its use.// ,The ... Prexige (generic name, lumiracoxib) available from Tuesday. The drug is ... it was found in 2004 that these group of drugs ...
... have suggested that cross-immunity created in response to infection ... //,by related serotypes thus leading to the waxing and ... help understand the pattern of this deadly mosquito-borne illness ... 1980s, there's been a sequential replacement of the dominant ...
... Indiana University School of Medicine it was found that ... the life span of those suffering from compromised immune ... the journal of Biological Chemistry. These proteins can be ... boost the patient’s immune system. The lead researcher Roman ...
... been criticized severely because a staff nurse has refused to send ... Mary Smith, 87 had an agonizing pain in her lower abdomen. ... replied that she could not have an ambulance and had to ... her. Then when the GP arrived he just gave her some ...
... minds of many cancer survivors. After treatment, as life ... makers now //,consider a chronic condition, survivors need to ... choices to ensure quality-of-life. This national movement, commonly referred ... year. ,Steps for Living (SFL), a nonprofit ...
Cached Medicine News:Health News:Thrombosis, a Serious Risk in Children with Leukemia 2Health News:New Arthritis Drug Linked to Increased Risk of Heart Attacks 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 3Health News:New Music Project Promotes Quality-of-Life After Cancer 2
... Easyfield is lightweight enough to shuttle ... carrying case. Designed with a goldmann standard ... fixed-point grid with 79 locations (including 30-2, ... and 3 different suprathresholds out to 30. ...
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
... additional hardware and software features to meet ... clinics or teaching institutions. Standard with B/Y ... for experimental or clinical studies. Ethernet connection ... further tests including Flicker- and Color perimetry, ...
... Designed around the patented ... Octopus 301 sets the trend ... decade. Ideal for routine screening ... performance, accuracy and quality ...
Medicine Products: